AbbVie’s Immunology Growth Strategy Is Delivering, But Imbruvica Reduced By IRA

 
• By Joseph Haas
Writeoff
AbbVie has written down Imbruvica's value by $2.1bn • Source: Shutterstock

More from Earnings

More from Business